ATC Group: M03AX01 Botulinum toxin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M03AX01 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M03 Muscle relaxants
3 M03A Muscle relaxants, peripherally acting agents
4 M03AX Other muscle relaxants, peripherally acting agents
5 M03AX01 Botulinum toxin

Active ingredients in M03AX01

Active Ingredient

Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).

Botulinum toxin type B is a neuromuscular blocking agent indicated for the treatment of cervical dystonia. When injected directly into a muscle, it causes a localised paralysis that gradually reverses over time.

Related product monographs

Document Type Information Source  
 ALLUZIENCE Solution for injection MPI, EU: SmPC Health Products Regulatory Authority (IE)
 AZZALURE Powder for solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 BOTOX Powder for solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 LETYBO Powder for solution MPI, US: SPL/PLR FDA, National Drug Code (US)
 NEUROBLOC Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 NUCEIVA Powder for solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 XEOMIN Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.